Presumed radically treated renal cell carcinomaRecurrence of the disease and prognostic factors for subsequent survival
| Autor: | Christian Beisland, Hans Olav Beisland, Per Christian Medby |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Nephrology medicine.medical_specialty Adolescent Urology medicine.medical_treatment Nephrectomy Risk Assessment Gastroenterology Statistics Nonparametric Metastasis Age Distribution Predictive Value of Tests Renal cell carcinoma Internal medicine medicine Carcinoma Humans Neoplasm Invasiveness Sex Distribution Carcinoma Renal Cell Aged Neoplasm Staging Probability Retrospective Studies Aged 80 and over business.industry Incidence Retrospective cohort study Middle Aged Prognosis medicine.disease Survival Analysis Kidney Neoplasms Surgery Treatment Outcome Multivariate Analysis Female Neoplasm Recurrence Local business Kidney cancer Kidney disease |
| Zdroj: | Scandinavian Journal of Urology and Nephrology. 38:299-305 |
| ISSN: | 1651-2065 0036-5599 |
| DOI: | 10.1080/00365590410028818 |
| Popis: | To gain knowledge about when, where and how metastases after presumed radical treatment for renal cell carcinoma (RCC) are detected, and to use this information to establish a follow-up programme for radically treated RCC. Further aims were to establish survival rates, together with identifying prognostic factors influencing survival for different groups of patients after recurrence of the disease.A retrospective study of 305 pT1-4N0M0/pT1-4NxM0 (clinically N0) tumours treated with nephrectomy was performed.A total of 89 patients (29.2%) developed metastases, with a median time to recurrence of 25.1 months. Within 5 years, 80% of the metastases had been detected. The lungs were the commonest metastatic site. A total of 34.8% of the recurrences were diagnosed as a result of routine follow-up. Median cancer-specific survival (CSS) after recurrence was 9.8 months. For patients with a disease-free interval (DFI)or =24 months the median CSS was 35 months. In a univariate analysis, performance status, DFIor =24 months, metastases in a single organ, primary tumour sizeor =70 mm, primary tumour stage pT1-2 and age65 years were all associated with better survival. In a multivariate analysis, performance status, DFI and number of organs affected were independent predictors of survival.The information from this material is used to suggest a simple, but adequate, follow-up protocol. Easily accessible information can be used to identify groups with different prognoses regarding survival after recurrence of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|